The impact of hyporesponsiveness to erythropoietin-stimulating agents on time-dependent mortality risk among CKD stage 5D patients: a single-center cohort study
Clinical and Experimental Nephrology, 07/05/2012
Ishigami J et al. – Hyporesponsiveness to erythropoietin–stimulating agents was associated with an increased risk of mortality. There was no sign of increased mortality risk associated with epoetin itself up to a total dose of 9000 U/week.